Green Planet Bioengineering Co Ltd (GPLB) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerGreen Planet Bioengineering Co Ltd (GPLB) trades at $0.029. Green Planet Bioengineering Co. Ltd. is a shell company focused on acquiring and merging with an existing business. Founded in 2006, the company currently operates without active business operations. Sector: Financials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for GPLB: GPLB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
Green Planet Bioengineering Co Ltd (GPLB) Financial Services Profile
Green Planet Bioengineering Co. Ltd., established in 2006, functions as a shell company seeking acquisition and merger opportunities within the financial services sector. Currently without active operations, GPLB aims to identify and integrate with an existing business, presenting a high-risk, high-reward profile for investors.
What Is the Investment Thesis for GPLB?
Investing in Green Planet Bioengineering Co. Ltd. (GPLB) is highly speculative, given its status as a shell company with no current operations. The potential upside lies in the company's ability to successfully acquire and merge with a promising business, which could drive significant value creation. However, the lack of current revenue, a negative P/E ratio of -10.58, and a negative beta of -1.15 indicate substantial risk. Investors should carefully consider the potential for dilution, the uncertainty surrounding the acquisition target, and the overall speculative nature of this investment. The company's success is entirely dependent on its future acquisition strategy.
Based on FMP financials and quantitative analysis
GPLB Key Highlights
Green Planet Bioengineering Co. Ltd. operates as a shell company, focusing on mergers and acquisitions within the financial services sector.
- The company's market capitalization is $0.00B, reflecting its current lack of operational activity.
- GPLB's P/E ratio is -10.58, indicating negative earnings and the absence of profitability.
- The company's beta is -1.15, suggesting an inverse correlation with market movements and potentially lower volatility compared to the broader market.
- Green Planet Bioengineering does not offer a dividend, consistent with its status as a shell company focused on future acquisitions.
Who Are GPLB's Competitors?
GPLB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BYSD Bayside Corporation | $0.97 | 0.00% | $15.8M | — |
| MTRI Metro Inc. | $15.24 | -0.26% | $889M | 38 5-pillar |
| DMII Drugs Made In America Acquisition II Corp. | $10.26 | +0.29% | $654M | 49 5-pillar |
| BCSS Bain Capital GSS Investment Cor | $10.41 | +0.68% | $608M | 55 5-pillar |
| CEPF Cantor Equity Partners IV, Inc. | $10.32 | -0.00% | $590M | 50 5-pillar |
| UMAC UMAC | $9.61 | -4.28% | $499M | — |
| NPAC New Providence Acquisition Corp. III | $10.59 | +0.14% | $407M | 50 5-pillar |
| CLBR Colombier Acquisition Corp. | $10.03 | -0.20% | $401M | 52 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GPLB's Key Strengths?
Clean slate with no legacy issues.
- Flexibility to pursue various acquisition targets.
- Potential for significant value creation through a successful acquisition.
- Existing public listing provides access to capital markets.
What Are GPLB's Weaknesses?
No current revenue or operations.
- High dependence on management's ability to identify and execute a successful acquisition.
- Significant uncertainty regarding the future direction of the company.
- Potential for dilution through future equity offerings.
What Could Drive GPLB Stock Higher?
GPLB catalyst: Announcement of a potential acquisition target, which could drive investor interest and increase the stock price.
- Efforts to identify and evaluate potential acquisition opportunities.
- Changes in market conditions that make acquisitions more attractive.
What Are the Key Risks for GPLB?
Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Failure to identify a suitable acquisition target, which could lead to the company's dissolution.
- Unsuccessful integration with the acquired business, resulting in financial losses.
- Limited financial disclosure and lack of regulatory oversight.
- Low liquidity and high price volatility.
- Dilution of existing shareholders through future equity offerings.
What Are the Growth Opportunities for GPLB?
- Acquisition of a Fintech Company: Green Planet Bioengineering could target a rapidly growing fintech company to capitalize on the increasing demand for digital financial services. The global fintech market is projected to reach $697.5 billion by 2030, growing at a CAGR of 23.42% from 2023. A successful acquisition in this space would provide GPLB with immediate revenue streams and a strong growth trajectory.
- Merger with a Sustainable Investment Firm: Given the increasing focus on ESG investing, Green Planet Bioengineering could merge with a sustainable investment firm. This merger would allow GPLB to tap into a growing market segment and attract socially responsible investors.
- Acquisition of an Asset Management Company: Green Planet Bioengineering could acquire an asset management company to generate stable revenue through management fees. This acquisition would provide GPLB with a diversified portfolio of assets and a steady income stream.
- Merger with a Blockchain Technology Company: Green Planet Bioengineering could merge with a blockchain technology company to leverage the growing adoption of blockchain in financial services. This merger would position GPLB at the forefront of technological innovation in the financial sector.
- Acquisition of a Specialty Finance Company: Green Planet Bioengineering could acquire a specialty finance company focused on niche lending markets. These companies often generate higher margins due to reduced competition and specialized expertise. This acquisition would allow GPLB to diversify its revenue streams and target underserved market segments.
What Opportunities Does GPLB Have?
- Acquire a high-growth business in a rapidly expanding market.
- Merge with a company with complementary strengths and synergies.
- Capitalize on undervalued assets or distressed businesses.
- Attract strategic investors to support future growth.
What Threats Does GPLB Face?
- Inability to identify a suitable acquisition target.
- Failure to successfully integrate with the acquired business.
- Increased competition from other shell companies and investment firms.
- Changes in market conditions or regulatory environment.
What Are GPLB's Competitive Advantages?
- As a shell company, Green Planet Bioengineering Co. Ltd. does not currently possess a traditional economic moat.
- The company's potential moat will depend on the competitive advantages of the business it acquires.
- Potential moats could include proprietary technology, brand recognition, or a strong market position.
What Does GPLB Do?
Green Planet Bioengineering Co. Ltd. was founded on October 30, 2006, and is headquartered in Aventura, Florida. The company's primary purpose is to identify, acquire, and merge with an existing operating business. As a shell company, Green Planet Bioengineering currently does not have any active business operations or generate revenue. The company's strategy revolves around finding a suitable target for acquisition, which would then allow it to enter a specific market or industry. The success of Green Planet Bioengineering hinges on its ability to identify and successfully integrate with a viable business. The company's future direction and market positioning are entirely dependent on the nature of the business it ultimately acquires.
What Products and Services Does GPLB Offer?
- Green Planet Bioengineering Co. Ltd. functions as a shell company.
- The company seeks to acquire an existing business operation.
- GPLB aims to merge with the acquired business.
- The company is currently not engaged in active business operations.
- GPLB's primary activity is identifying potential acquisition targets.
- The company intends to use the acquisition to enter a specific market or industry.
How Does GPLB Make Money?
- Green Planet Bioengineering's business model is centered around identifying and acquiring an existing operating company.
- The company intends to merge with the acquired entity to create a new business operation.
- GPLB's revenue model will depend on the business it ultimately acquires.
What Industry Does GPLB Operate In?
Green Planet Bioengineering Co. Ltd. operates within the financial conglomerates industry, a segment characterized by companies that hold a variety of investments and businesses across different sectors. The industry is influenced by macroeconomic trends, regulatory changes, and investor sentiment. As a shell company, GPLB's success depends on its ability to navigate this landscape and identify a suitable acquisition target. The competitive landscape includes other shell companies and investment firms seeking similar opportunities. The company's future performance is tied to its ability to execute a successful merger or acquisition strategy.
Who Are GPLB's Key Customers?
- As a shell company, Green Planet Bioengineering Co. Ltd. does not currently have customers.
- The company's future customer base will depend on the nature of the business it acquires.
- Potential customers could include businesses or consumers depending on the acquired entity's operations.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Financial Health
Green Planet Bioengineering Co Ltd's Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Green Planet Bioengineering Co Ltd stands at 8.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -27.4%, a gauge of the cash the business throws off relative to its market value. Its earnings yield is -20.8%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Green Planet Bioengineering Co Ltd operates in the Financial Services sector. It is headquartered in Aventura, US. The company is led by CEO Jordan Weingarten. GPLB has traded publicly since 2012.
GPLB Financials
Bull Case vs Bear Case
Bull Case
- Clean slate with no legacy issues.
- Flexibility to pursue various acquisition targets.
- Potential for significant value creation through a successful acquisition.
- Existing public listing provides access to capital markets.
Bear Case
- No current revenue or operations.
- High dependence on management's ability to identify and execute a successful acquisition.
- Significant uncertainty regarding the future direction of the company.
- Potential for dilution through future equity offerings.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GPLB Latest News
No recent news available for GPLB.
GPLB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for GPLB.
Price Targets
Wall Street price target analysis for GPLB.
GPLB MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for GPLB; grades run from A+ (80-100) to F (below 30).
Leadership: Jordan Weingarten
CEO
Jordan Weingarten serves as the CEO of Green Planet Bioengineering Co. Ltd. His background includes experience in financial management and corporate strategy. He has been involved in various investment and business development projects. His expertise lies in identifying and evaluating potential business opportunities, structuring deals, and managing financial resources. Weingarten's leadership is focused on guiding Green Planet Bioengineering through its acquisition and merger strategy.
Track Record: Jordan Weingarten's track record includes overseeing the company's efforts to identify and evaluate potential acquisition targets. His strategic decisions have focused on positioning the company for a successful merger or acquisition. Under his leadership, Green Planet Bioengineering has been actively exploring opportunities in various sectors. His experience in financial management is crucial for navigating the complexities of the acquisition process.
GPLB OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Green Planet Bioengineering Co. Ltd. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and trading activity may be thin. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. This tier is generally reserved for companies with distressed financials, limited operating history, or those that are not current in their reporting obligations.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The lack of comprehensive financial reporting increases the difficulty of assessing the company's true financial condition.
- Low Liquidity: Limited trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Potential for Fraud or Manipulation: The OTC Other tier is subject to less regulatory oversight, increasing the risk of fraudulent activity.
- Going Concern Risk: Companies in this tier may have significant financial challenges and a high risk of bankruptcy.
- Shell Company Risk: As a shell company, GPLB's value is entirely dependent on a future acquisition, which may not occur or may not be successful.
- Verify the company's registration and legal standing.
- Review any available financial statements and disclosures.
- Assess the management team's experience and track record.
- Research the company's potential acquisition targets.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before investing.
- Monitor the company's news and filings for any updates.
- Presence of a CEO and management team.
- Company registration and legal compliance.
- Active efforts to identify acquisition targets.
- Publicly traded status provides some level of transparency.
- Engagement with investors and stakeholders.
Green Planet Bioengineering Co Ltd Financials Stock: Key Questions Answered
Is GPLB a good stock to buy?
Stock Expert AI does not rate GPLB buy, sell or hold. Green Planet Bioengineering Co Ltd has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the GPLB stock price today?
The last price recorded on this page for Green Planet Bioengineering Co Ltd (GPLB) is $0.029, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Green Planet Bioengineering Co Ltd do?
Green Planet Bioengineering Co. Ltd. operates as a shell company, meaning its primary purpose is to acquire or merge with an existing business. Currently, GPLB has no active business operations and generates no revenue.
What do analysts say about GPLB stock?
As of 2026-03-17, there is no available analyst coverage for Green Planet Bioengineering Co. Ltd. given its status as a shell company with no active operations. Key valuation metrics such as revenue, earnings, and cash flow are not applicable in its current state.
What are the key factors to evaluate for GPLB?
Evaluate GPLB on fundamentals, analyst consensus, and risk factors. Investing in Green Planet Bioengineering Co. Ltd. (GPLB) is highly speculative, given its status as a shell company with no current operations. Not financial advice.
How frequently does GPLB data refresh on this page?
GPLB's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven GPLB's recent stock price performance?
Green Planet Bioengineering Co Ltd (GPLB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Clean slate with no legacy issues. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GPLB overvalued or undervalued right now?
Green Planet Bioengineering Co Ltd (GPLB) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the nature of the company.